Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06548386 · ClinicalTrials.gov registry record · NA

Feasibility and Accuracy of a Novel Pleural Drain Gas Analyzer in Detecting Air Leaks

A NA study of Pneumothorax and Air Leak From Lung, sponsored by Lung Healing Technologies.

Recruiting
Registry status
NA
Development phase
33
Enrollment target
1
Study location

NCT06548386: Recruiting NA study of Pneumothorax and Air Leak From Lung, sponsored by Lung Healing Technologies.

NCT06548386 is a NA study of Pneumothorax and Air Leak From Lung that is actively recruiting participants, run by Lung Healing Technologies. The registered enrollment target is 33 participants, below the 639-participant average among 6 other Pneumothorax trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06548386, a NA study of Pneumothorax and Air Leak From Lung, is actively recruiting participants, sponsored by Lung Healing Technologies.

RECRUITING
Registry status
NA
Development phase
33 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to assess the clinical feasibility of a novel, reusable, low cost gas analyzer that detects breath in chest drains in order to diagnose and heal air leaks. The investigators have developed prototype gas analyzers that attach to the outlet of any analog chest drain, and can be connected temporarily to the sampling port. They detect breath by measuring CO2, O2, and pressure, in order to supplement the information provided by the bubbles in the water seal.

Primary Outcome

Whether gas analysis can accurately assess for air leak

Interventions

  • DEVICE Pleural gas analysis

Study Locations (1)

Illinois

  • Endeavor Health - Evanston

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2025-02-05
Est. Completion 2026-06
Phase NA
Lung Healing Technologies

1 total trials

What NCT06548386 shows while recruiting

NCT06548386 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 639-participant average among 6 other Pneumothorax trials with a reported enrollment target (95% lower).

The record links to 2 conditions, with Pneumothorax appearing as the primary indexed condition, and to 1 intervention - of which Pleural gas analysis is the first listed.

NCT06548386 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT06548386 about?

NCT06548386 is a clinical study titled "Feasibility and Accuracy of a Novel Pleural Drain Gas Analyzer in Detecting Air Leaks". The goal of this study is to assess the clinical feasibility of a novel, reusable, low cost gas analyzer that detects breath in chest drains in order to diagnose and heal air leaks. The investigators have developed prototype gas analyzers that attach to the outlet of any analog chest drain, and can ...

What is the current status of trial NCT06548386?

This trial is currently recruiting. It is a NA study. The enrollment target is 33 participants. The study started on 2025-02-05. Estimated completion is 2026-06.

What conditions does trial NCT06548386 study?

This clinical trial studies the following conditions: Pneumothorax, Air Leak From Lung.

What interventions are being tested in trial NCT06548386?

The interventions under investigation include: Pleural gas analysis (DEVICE).

Who is sponsoring clinical trial NCT06548386?

This trial is sponsored by Lung Healing Technologies, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06548386 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pneumothorax

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02861898 · 33 participants · Phase 1

    Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

  • NCT04871607 · 33 participants · Phase 2

    Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

  • NCT05071937 · 33 participants · Phase 2

    ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

  • NCT05168618 · 33 participants · Phase 2

    Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06548386, the US trial registry maintained by the National Library of Medicine. NCT06548386 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.